Today's Healthcare Pulse
Pharma Shifts Ad Spend to Spot TV Amid Heightened FDA Scrutiny
Pharmaceutical advertisers are redirecting dollars toward spot television placements as the FDA intensifies its oversight of drug marketing. The trend reflects a strategic move to capture audiences with shorter, targeted ads while navigating tighter regulatory expectations.
Also developing:
By the numbers: Apogee Therapeutics secures $1.3B royalty financing
NYU Langone mRNA Vaccine Cuts Melanoma Recurrence Risk by 49% in 5‑Year Study
NYU Langone Health’s Perlmutter Cancer Center reported that the personalized mRNA vaccine intismeran, when combined with pembrolizumab, lowered the five‑year risk of melanoma recurrence or death by 49% compared with pembrolizumab alone. The data, presented at ASCO and published in the Journal of Clinical Oncology, also showed a 59% drop in distant metastasis and an overall survival advantage of 21 percentage points.
A Medical School Experience that Redefined Providing Care
A first‑year medical student recounts using a stethoscope on a friend, mistakenly diagnosing a simple cough as harmless and later learning it was walking pneumonia. The episode revealed how the white coat and stethoscope instantly confer perceived authority, even without...
Physician Burnout Is Quietly Costing Doctors Themselves
Physician burnout is now seen as a silent crisis that strips doctors of their personal identity, not just their stamina. Dr. Gani describes how relentless patient loads, endless inboxes, and late‑night charting leave primary‑care physicians emotionally numb and disconnected from...
Nigeria Cuts Facility Maternal Deaths by Half After Health System Overhaul
A 2025 government health report shows Nigeria’s facility‑based maternal deaths fell from 904 in 2024 to 460 in 2025 – a near‑50% reduction. The decline coincides with higher skilled birth attendance, broader emergency obstetric care coverage and revamped referral networks,...
UBS Lifts Jazz Pharma Price Target to $307, Upgrades to Buy
UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) to Buy on May 19, raising the price target from $188 to $307 – a 63% jump that eclipses the prior consensus of $242. The move comes ahead of the August 25...
KAIST Launches AI Interviewer to Cut Psychiatric Intake to 30 Minutes
KAIST announced on April 24 that its research team unveiled an AI‑driven interview system capable of collecting psychiatric intake information in 30 minutes. Validated on 1,440 simulated patients, the tool structures symptom data before the clinician sees the patient, promising faster,...
Elevance Health Posts Q1 Earnings Momentum, Expands Integrated Benefits Strategy
Elevance Health reported stronger first‑quarter 2026 earnings, driven by higher premium revenue and growth in government‑backed programs, while outlining an expanded integrated health‑benefits and care‑management strategy. The results underscore the insurer's dual‑model resilience and set the tone for the broader...
WHO Member States Adopt 10‑Year Global AMR Strategy Targeting 10% Death Reduction
WHO Member States approved a new 10‑year global action plan on antimicrobial resistance, pledging to reduce AMR‑related deaths by 10% by 2030. The strategy shifts focus from new drug development to prevention, infection control and equitable technology transfer, amid a...
HHS Goes All-In on ChatGPT for State Audits: What the May 2026 Generative AI Fraud Expansion and February’s CRUSH RFI...
On May 21, 2026 the U.S. Health and Human Services Department (HHS) launched an internal workflow that feeds single audit PDFs into ChatGPT and other large language models to flag chronic deficiencies and threaten funding cuts. The move builds on...
Distributors Accept Near‑Retail Prices, Driving High Drug Costs
Let me give you an example of where there is no gov intervention, and the impact on brand drug pricing. When a brand manufacturer sells a drug to one of the big 3 drug distributors that control more than...
FDA Approves Datroway, First TROP2‑ADC for First‑Line Metastatic Triple‑Negative Breast Cancer
The U.S. FDA has approved Datroway (datopotamab deruxtecan‑dlnk), the first TROP2‑directed antibody‑drug conjugate for first‑line treatment of metastatic triple‑negative breast cancer in patients ineligible for PD‑1/PD‑L1 inhibitors. The approval follows a Phase 3 trial that demonstrated a median overall‑survival improvement of...
Ebola Spreads Across Congo as Flights Halted, Supplies Run Low
Ebola cases in the Democratic Republic of Congo have surged to an estimated 867, with more than 200 deaths, as the rare Bundibugyo strain spreads across three provinces. Contact‑tracing efforts are faltering, covering only about 20% of identified contacts, and...
Declining Trust in Doctors Is Widening the Health Gap Between Conservative and Liberal Americans
A new study published in Nature Human Behaviour finds that conservative Americans now experience worse health and higher mortality than liberals, a gap that widened after 2010. Researchers linked individual political orientation to verified medical measurements and death records, revealing...
Smarter Engagement for Stronger Growth: How Payers Can Successfully Do More with Less
Health insurers are confronting a paradox: extensive digital tools exist, yet member engagement remains low and fragmented. Steve Mongelli argues that the core issue is not technology scarcity but an orchestration problem, with siloed platforms and a sprawling vendor ecosystem....
Federal Court Strikes Down Landmark Fluoride Ruling
A three‑judge panel of the 9th U.S. Circuit Court of Appeals vacated the district court’s finding that fluoridated drinking water poses an unreasonable risk to children under the Toxic Substances Control Act. The appellate court ruled the lower court violated...
The Top 10 Side Effects of GLP-1 Drugs - What You Need to Know
GLP‑1 receptor agonists such as Ozempic, Wegovy, Mounjaro and Zepbound trigger a spectrum of adverse effects, with nausea and vomiting reported in up to half of patients and 16‑36% respectively. Gastrointestinal disturbances—diarrhea, constipation, abdominal pain—are common, while rarer but serious...
How State Laws Can Stymie Research Into Your Ancestors' Psychiatric Records
State laws across the U.S. tightly restrict access to historic psychiatric records, leaving families unable to retrieve mental‑health information about deceased ancestors. While HIPAA protects patient data for 50 years after death, some states such as Ohio and Maine already...
Viking Therapeutics Emerges as Prime Obesity‑Drug Acquisition Target
Viking Therapeutics is being touted as a leading acquisition candidate after its late‑stage GLGL‑1/GIP obesity drug VK2735 showed 12.2%‑14.7% weight loss in Phase 2 trials and its Phase 3 VANQUISH studies are fully enrolled. With $603 million in cash and a market cap...
How GLP-1 Medications Compare to Bariatric Surgery
GLP‑1 receptor agonists such as semaglutide and tirzepatide now deliver 15‑20% average weight loss, a range once reserved for bariatric surgery. Oral formulations are in late‑stage trials, promising to remove injection barriers for many patients. While FDA approval remains limited...
Your Brain Restricts Full Access to Reality. But Scientists Found a Way to Turn Off the Filter.
Neuroscientists are revisiting the thalamus as more than a sensory relay, arguing it actively filters and stitches together sensory input into a unified conscious stream. A 2024 *Neuron* review led by Stanford’s Michelle Redinbaugh posits that this gating mechanism stabilizes...
Consider Hernia First in Women’s Chronic Pelvic Pain
Femoral hernias kill 5% of the women who get them. Women are 10 times more likely than men to have them. Six randomized trials have enrolled seven women total. That is the actual research foundation behind how we manage one...
Cancer Immunotherapy Surge: Emerging Treatments and Future Outlook
I wrote about the remarkable proliferation of cancer immunotherapies, and what's in store https://t.co/od4MeFMGik https://t.co/5jI10LLbLq
NHS WorkWell Pilots Replace Fit Notes, Aiming for 100,000 Appointments
The NHS has launched WorkWell pilots that replace traditional fit notes with up to 100,000 support appointments across six regions. The scheme offers physiotherapy, mental‑health help and workplace coaching, aiming to get patients back to work faster.
BCI Controls Neuroprosthetic Grasps via Surface and Implanted Electrodes
“application of a BCI as a control system for neuroprostheses based on surface (a) and implanted (b) electrodes, respectively. (c) grasp pattern for palmar grasp. (d) grasp pattern for lateral grasp” https://t.co/TUIIbe84hi
Self‑collected HPV Tests Could Boost Cervical Cancer Screening
What at-home HPV testing means for cervical cancer screening Pap smears transformed cervical cancer prevention. Now, self-collected HPV testing may help more women stay up to date on screening. https://t.co/EA20D8vqBF https://t.co/5j9JDu6svX
Predicting Alzheimers & Dementia (and Minimizing Risk)
Recent preclinical work shows rapamycin clears soluble tau and amyloid by boosting autophagy, improving cognition in multiple AD mouse models. Human brain studies reveal chronic mTORC1 hyperactivation correlates with plaque and tangle burden, while transplant patients on mTOR inhibitors exhibit...
BeamMed Rolls Out Portable Bone Density Scanner and AI Fundus Camera at Medicare Stars HEDIS Forum
BeamMed Inc. is exhibiting its MiniOmni portable bone density scanner and AI‑powered fundus camera at the 15th Medicare Stars HEDIS Quality & Risk Forum in Chicago (June 2‑4, 2026). The devices target the HEDIS Osteoporosis Management in Women (OMW) and Osteoporosis Screening...
Pharming Group Secures EU Approval for Joenja, First Treatment for Rare Immunodeficiency
Pharming Group announced that the European Commission granted marketing authorisation for Joenja (leniolisib), the first approved therapy for activated PI3K delta syndrome (APDS) in the EU. The approval, covering all 27 EU members plus Norway, Iceland and Liechtenstein, paves the...
Deep Generative Molecular Design and Its Value in Modern Drug Discovery (Paper Feb 26)
The February 2026 review maps the rapid rise of deep generative molecular design in drug discovery, arguing that AI is moving from virtual screening toward the creation of new, testable drug hypotheses. It categorises the field into three technical families—graph‑based...
Self-Tests Need Accountable Follow-Up Pathways
A letter to the BMJ highlights that the UK Medicines and Healthcare products Regulatory Agency (MHRA) must tighten rules for direct‑to‑consumer self‑tests. Recent BMJ studies show many kits omit basic user guidance, result interpretation, and clear next‑step instructions, forcing patients...
Sepsis From C. Difficile Infection Has Comparable Mortality
A new propensity‑score‑matched analysis published in Scientific Reports shows that sepsis triggered by Clostridioides difficile infection carries a mortality risk indistinguishable from sepsis caused by other pathogens. By balancing age, comorbidities, illness severity and treatment variables, the study isolates the...
AI Blood Test Predicts Stroke, Heart Failure and More Up to 15 Years Early
Researchers at the University of Hong Kong have launched CardiOmicScore, an AI‑driven blood test that predicts six major cardiovascular diseases up to 15 years before clinical onset. The tool outperforms traditional polygenic risk scores by integrating genomics, proteomics and metabolomics,...
EMA Gives Positive Opinion on Serplulimab for First‑Line Squamous NSCLC
The European Medicines Agency (EMA) issued a positive opinion on serplulimab, marketed as HETRONIFLY, for use as a first‑line treatment of squamous non‑small cell lung cancer (NSCLC). The endorsement comes from Shanghai Henlius Biotech, the drug’s developer, and signals a...
Abbott Launches New Cardiovascular Diagnostics and Wearables, Expanding Digital Health Portfolio
Abbott Laboratories unveiled a suite of cardiovascular diagnostics and wearable devices, including the Lingo biomarker platform, to deepen its digital‑health footprint. The move comes as the stock climbs 3.5% over the past week, offering investors a fresh growth narrative amid...
Rovex Unveils Rovi, Claiming First Autonomous In‑Hospital Patient Transport Robot
Florida‑based robotics startup Rovex unveiled Rovi, a robot it claims is the world’s first autonomous in‑hospital patient transport system. The device uses computer‑vision navigation, universal stretcher attachments and data‑capture tools to ease bottlenecks in imaging, procedures and bed turnover.
UnitedHealth Invests $1.6 B in AI, Launches Avery Chatbot for 6.5 M Members
UnitedHealth Group announced a $1.6 billion AI investment and the rollout of its generative‑AI chatbot Avery to 6.5 million members, with a goal of serving 20 million by year‑end. The moves helped lift the stock 53% since March and lowered the medical benefit...
Florida Nurse Charged with $1.35 M Medicaid Fraud Involving Incarcerated and Deceased Patients
Marisol Rodriguez, a 49‑year‑old advanced practice registered nurse from Lehigh Acres, Florida, was arrested on federal charges for submitting more than 15,000 fraudulent Connecticut Medicaid claims totaling $1.35 million. The alleged scheme billed for medication‑management services that were never provided, even...
Merck Gets EU CHMP Nod for KEYTRUDA‑Padcev Combo in Bladder Cancer
Merck announced that the European Medicines Agency’s CHMP has issued a positive recommendation for its KEYTRUDA plus Padcev regimen in resectable muscle‑invasive bladder cancer, sending the stock up 2.57% to $118.85. The endorsement, based on the Phase 3 KEYNOTE‑905 trial conducted...
ZNF274 Blocks Lineage Switch, Fuels CDK7 Drug Resistance
Researchers published in Nature Communications that the zinc‑finger protein ZNF274 acts as a molecular gatekeeper in pancreatic cancer, limiting lineage plasticity and preserving sensitivity to CDK7 inhibitors. Loss of ZNF274 triggers enhancer reprogramming, epithelial‑to‑mesenchymal transition and transcriptional heterogeneity, enabling cells...
Community-Based Baby Hip Screening Successfully Reduces Late Diagnosis of Developmental Dysplasia
A nurse‑led, community‑based ultrasound program in Japan screened 349 infants for developmental dysplasia of the hip (DDH), achieving 95.6% coverage. The trial identified 8.7% of babies with suspected DDH, including many without clinical risk factors, and referred 42 infants for...
AI Systems Slash Drug Discovery Time, Yield New Cancer and Neurodegenerative Candidates
FutureHouse’s Robin and DeepMind’s Co‑Scientist AI agents have collapsed drug‑candidate timelines by up to 200‑fold, while NIH’s TRANSLATE‑AI has identified three repurposed drugs for Alzheimer’s and Parkinson’s with 98% pre‑clinical accuracy. The breakthroughs promise faster routes to clinical trials for...
China Rolls Out First National Longevity Medicine Training Program
China's health authorities, together with the China Non‑public Medical Institutions Association and the Asia‑Pacific Longevity Medicine Society, launched the country's first national, competency‑based training program in longevity medicine. The curriculum targets licensed physicians across specialties and seeks to embed preventive,...
FDA Grants First U.S. Approval for Bulevirtide, Gilead’s Hepatitis D Therapy
The FDA approved Gilead Sciences' bulevirtide‑gmod (Hepcludex) on May 22, 2026, marking the first U.S. therapy for chronic hepatitis delta virus. The drug earned accelerated approval, priority review, breakthrough therapy and orphan‑drug designations after a phase‑3 trial showed a 48%...
Novo Nordisk Cuts Drug Launch Time by Two‑Thirds Using AI, Expands India Hub
Novo Nordisk announced that artificial‑intelligence tools are trimming new‑drug launch cycles by as much as two‑thirds, with its Bengaluru, India centre now handling a majority of preparatory work for global rollouts. The move aims to recapture momentum in the fast‑growing...
AbbVie’s MAVIRET Wins Positive CHMP Opinion, 96% Cure Rate for Acute Hepatitis C
AbbVie announced that the European Medicines Agency’s CHMP has issued a positive opinion on MAVIRET for acute hepatitis C, citing a 96% cure rate in an eight‑week Phase 3 trial. The recommendation paves the way for EU approval in the third...
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
Starting July 2026, Medicare will pilot a GLP‑1 Bridge program that covers weight‑loss drugs such as Wegovy, Zepbound and Foundayo for a flat $50 monthly copayment. Eligibility hinges on a BMI of 27 or higher with a qualifying condition, or...
Healium Clinical Secures FDA Registration as Class II Biofeedback Device for Meditation Therapy
Healium announced that its VR‑enabled platform, Healium Clinical, has been registered with the U.S. FDA as a Class II 510(k)-exempt biofeedback medical device. The clearance clears a regulatory hurdle for immersive meditation‑based stress‑management tools and positions the company for broader clinical...
McKesson Posts $403B Record Revenue as AI Revamps Distribution Network
McKesson Corp. announced full‑year 2026 consolidated revenue of $403 billion, a 12% rise, while embedding artificial intelligence across its distribution, oncology and biopharma services. The AI rollout, highlighted by a new Montreal hub and a unified planning platform, helped generate $6.2 billion...
UN and AU Sign Landmark Agreement Guaranteeing Access to Safe Health Products
The World Health Organization and the African Medicines Agency have signed a five‑year Framework Agreement for Collaboration, announced at the 79th World Health Assembly. The pact aims to harmonize legal and regulatory frameworks across Africa, strengthening oversight of medical products...
Regeneron Reports Positive Phase 1/2 Data for Lynozyfic in Systemic AL Amyloidosis
Regeneron Pharmaceuticals released positive Phase 1/2 LINKER‑AL2 data for Lynozyfic in second‑line-plus systemic AL amyloidosis. The bispecific BCMAxCD3 antibody, built on VelociImmune technology, could become the first approved therapy after standard‑of‑care failure, a gap affecting thousands of patients.